摘要
严格控制胆固醇水平可以有效减少人群心血管病事件的发生,低密度脂蛋白胆固醇升高是动脉粥样硬化性心血管疾病的独立危险因素,可作为衡量胆固醇控制水平的主要指标。传统的管理胆固醇药物包括他汀类、胆固醇吸收抑制剂、胆酸螯合剂、贝特类临床疗效确切,而新型降胆固醇药物包括前蛋白转化酶枯草溶菌素9抑制剂、微粒体甘油三酯转运蛋白抑制剂、反义寡核苷酸(ApoB-100合成抑制剂)等同样取得了不错的临床疗效。文章将对胆固醇药物特点及其不良反应进行综述,以期找出最合理的胆固醇管理方案。
Control of cholesterol levels can reduces the incidence of atherosclerotic cardiovascular disease(ASCVD). Increased lowdensity lipoprotein cholesrerol has been an independent risk factor of ASCVD. Statins,cholesrerol absorption inhibitor,bile acid sequestrant have been proved effectively for reduction of low-density lipoprotein cholesterol. New type therapeutic drugs proprotein convertase subtilisin/kexin type 9 inhibitors,microsomal triglyceride transfer protein inhibitor,antisense oligonucleotide inhibitors,peroxisome proliferator-activated receptor-α have also achieved clinical benefit in recent clinical trials. In this article,we will review the efficacy and safty of cholesterol-lowering drugs,so that we can find out the most effective plan of cholesterol management.
作者
孙冰
王海昌
SUN Bing;WANG Haichang(Department of Medical Corp,Army of the PLA 96874,Baoji 721000;Department of Cardiology,Heart Hospital,Xi’an International Medical Center,Xi’an 710077,China)
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2021年第10期1546-1551,共6页
Journal of Nanjing Medical University(Natural Sciences)
